Keywords
Elasticity imaging techniques
Fatty liver
Body mass index
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the degree of hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), using transient hepatic elastography (THE or FibroScan®) in a group of patients treated at the Hepatology Outpatient Clinic of the Fundação Santa Casa de Misericórdia do Pará. Methods: This is a longitudinal, prospective, and observational study, conducted through the application of a structured questionnaire. Patients over 18 years of age, of both sexes, and with a diagnosis defined by ICD-10 as Fatty (Change) Degeneration of Liver, Not Elsewhere Classified (K76.0), were included. Results: Patients with moderate/severe steatosis presented significantly higher body mass index (BMI) and liver stiffness values. The controlled attenuation parameter (CAP) was also significantly higher in groups with advanced fibrosis (F3–F4). BMI showed a significant association with steatosis in the logistic regression analysis. No variable was significantly associated with fibrosis in the regression model. Finally, the model explained 26.1% of the variance in the steatosis outcome. Conclusion: BMI and CAP proved to be useful noninvasive markers to identify greater severity of MASLD. Hepatic elastography plays a relevant role in the screening of patients with metabolic risk, although further studies with larger samples are required to validate these associations.
References
ANDRADE ZA. Regressão da Fibrose Hepática. Revista da Sociedade Brasileira de Medicina Tropical, 2005; 38 (6): 514-520.
BALLESTRI S, et al. A doença hepática gordurosa não alcoólica está associada a um risco quase duas vezes maior de diabetes tipo 2 e síndrome metabólica. Evidências de uma revisão sistemática e meta-análise. J Gastroenterol Hepatol, 2016; 31: 936–944.
BERGAMIN MFK, et al. Doença hepática gordurosa não alcoólica - revisão de literatura. Brazilian Journal of Health Review, 2023; 6 (6), 33349–33357.
COSTA DD, MALVEIRA CTM. Doença hepática esteatótica associada à disfunção metabólica: o papel da ultrassonografia. Revista Eletrônica Acervo Saúde, 2025; 25: e18250.
CUSI K, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care, 2025; 48(7): 1057-1082.
FERNANDES L, et al. Metabolic dysfunction-associated steatotic liver disease: an update on screening and therapeutic options: doença hepática esteatótica associada a disfunção metabólica: uma atualização do rastreio e opções terapêuticas. Med. Interna, 2024; 31(3): 153-60.
GUTIÉRREZ VM, ENCISO JAR. Elastografía hepática:¿ qué es, cómo se hace y cómo se interpreta? Radiología, 2018; 60 (3): 183-189.
HASHEM A, et al. Validation of a machine learning approach using FIB-4 and APRI scores assessed by the metavir scoring system: A cohort study. Arab Journal of Gastroenterology, 2021; 22(2), 88-92.
LE MH, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clinical and Molecular Hepatology, 2022, 28 (4): 841-850.
LIU WY, et al. VCTE-Prognosis Study Group. From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective. Gastroenterology, 2025; 169 (2): 326-336.
MIKOLASEVIC I, et al. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World Journal of Gastroenteroly, 2016; 22 (32): 7236-7251.
PORTINCASA P, et al. Metabolic dysfunction–associated steatotic liver disease: from pathogenesis to current therapeutic options. International Journal of Molecular Sciences. 2024; 25 (11): 5640.
POUWELS S, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocrine Disorders, 2022; 22(1).
PRADO LR, et al. Índices antropométricos no rastreio da doença hepática esteatótica associada à disfunção metabólica: uma revisão da literatura. Brazilian Journal of Health Review, 2025; 8 (2): e79370.
RYOO JH, et al. Associação clínica entre doença hepática gordurosa não alcoólica e o desenvolvimento de hipertensão. Journal of Gastroenterology and Hepatology. 2014; 29:1926–1931.
SANTOS I, et al. Caracterização clínica-epidemiológica de pacientes com cirrose hepática atendidos em um serviço de referência na Amazônia. Revista Eletrônica Acervo Saúde, 2024; 24(9): e17480.
SOCIEDADE BRASILEIRA DE HEPATOLOGIA (SBH). Elastografia Hepática: guia prático. São Paulo: SBH, 2020. Disponível em: https://sbhepatologia.org.br. Acessado em: 18 de outubro de 2025.
SOLER GLN, et al. Doença hepática gordurosa não-alcoólica: associação com síndrome metabólica e fatores de risco cardiovascular. Revista da Sociedade de Cardiologia do Estado do Rio de Janeiro (SOCERJ), 2008; 21 (2), 94-100.
SILVA LCM, et al. Ultrasound elastography in patients with fatty liver disease. Radiologia Brasileira, 2020; 53(1): 47-55.
STÅL P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World Journal of Gastroenterology, 2015; 21(39): 11077-11087.
STEFAN N, et al. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. The Lancet Diabetes & Endocrinology, 2025, 13, 134-148.
THE JAMOVI PROJECT. JAMOVI. (VERSION 2.3) [Computer Software]. Disponível em: https://www.jamovi.org.2022.
YOUNOSSI Z, et al. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Journal of Hepatology, 2018; 69 (6):1365-1370.
YOUNOSSI ZM, et al. Epidemiologia global da doença hepática gordurosa não alcoólica (DHGNA) e da esteato-hepatite não alcoólica (EHNA): uma revisão sistemática. Hepatologia, 2023; 77: 1335–1347.
WONG VW, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. American Journal of Gastroenteroly. 2012; 107: 1862-1871.